現像温度および時間のマンモフイルム特性に与える影響

The influence for developing temperature and processing time within film processing conditions was investigated using four mammographic films, Konica New CM, Fuji UM-MA HC, Kodak Min-R M and Kodak EB/RA (for rapid system). And Fuji UR-2, a double-emulsion film, was used as a control. Those sensitometric strips exposed by a sensitometer were processed in the different combinations of developing temperatures ranging from 28 to 36℃, processing times from 45 to 210 sec. Average gradient, relative speed and base plus fog obtained from the measured film characteristic curves were evaluated for the different developing temperatures and times. Fuji UR-2 was scarcely affected and mammographic films were greatly affected in the different combinations without an increase in base plus fog except EB/RA. In New CM, UM-MA HC and Min-R M, the average gradients and the relative speeds increased as the developing temperature was higher and the developing time was longer, but the increases were limit on the combination of 36℃ and 210 sec in New CM and UM-MA HC. In EB/RA, the average gradients were almost constant and the relative speeds increased slightly like the double-emulsion film. These results suggested that it would be possible to contribute to dose reduction and advancement of contrast in New CM, UM-MA HC and Min-R M by changing these processing parameters.フィルム処理条件において,現像温度と処理時間に対する影響を4種類のマンモグラフィ用フィルムKonica New CM, Fuji UM-MA HC,Kodak Min-R M,迅速処理用Kodak EB/RAについて調べた｡そして,比較基準用として両面乳剤フィルムFuji UR-2を用いた｡感光計で露光したフィルムを現像温度28～36℃,処理時間45～210秒で処理した｡特性曲線から得られたフィルム特性（平均階調度,相対感度,カブリ濃度）を異なる現像温度,現像時間に対して評価した｡UR-2はほとんど影響を受けず,マンモグラフィ用フィルムは,カブリ濃度が上昇することなく,現像条件の影響を大きく受けた。New CM, UM-MA HC,Min-R Mは現像温度の上昇,処理時間の延長に伴い,平均階調度と相対感度は増加した｡しかし,New CM, UM-MA HCの36℃,210秒で増加は限度に達した｡EB/RAの平均階調度は一定で,相対感度は両面乳剤フイルムと同 様にわずかな増加であった｡これらの結果は,New CM, UM-MA HC, Min-R Mにおいて,処理条件を変化させることにより,被曝低減,コントラスト向上に貢献できる可能性を示唆していた

Thymoma-associated Graft-versus-Host Disease-like Erythroderma

We report a 40-year-old woman with recurrent thymoma associated with myasthenia gravis, in whom an unusual form of erythroderma developed. A histological examination revealed a graft-versus-host disease (GVHD)-like reaction. After high-dose steroid therapy, the metastatic thymoma lesion in the abdominal cavity was reduced in size from 9.5 × 6 × 7.5 cm to 4 × 3 × 1 cm in diameter. Nevertheless, the GVHD-like erythroderma become aggravated, her condition worsened, and the patient finally suffered from respiratory failure and died of sepsis. A GVHD-like reaction may be a rare presentation of thymoma-associated immunological disorders such as myasthenia gravis or pure red cell aplasia. Herein, we discuss the present case and review pertinent reports of thymoma cases associated with GVHD

Surgical Treatment following Chemo-Targeted Therapy with Bevacizumab for Lung Metastasis from Colorectal Carcinoma: Analysis of Safety and Histological Therapeutic Effects in Patients Treated at a Single Institution

Background: Recently, therapeutic strategies for a metastasectomy from colorectal carcinoma after chemo-targeted therapy with bevacizumab have been presented, with which some uncommon but serious adverse events have been reported. However, only few reports have investigated the safety of lung resection after such therapy or the histological effects. We retrospectively analyzed the both of them at our institute. Methods: Of 69 colorectal carcinoma patients who underwent pulmonary metastasectomy procedures from 2009 to 2014, we investigated 11 who also received chemo-targeted therapy prior to surgery. Results: In addition to bevacizumab, 5 fluorouracil (FU)/leucovorin + oxaliplatin or capecitabine was given in 6 cases and 5 FU/leucovorin + irinotecan in 5 cases. The mean period from the end of chemo-targeted therapy to surgery was 2.7 ± 0.9 months. The response to therapy shown in imaging findings was progressive disease in 6, stable disease in 3, and partial response in 2 (response rate, 18.2%). The operation modes were wedge resection (n = 8, 72.3%), segmentectomy (n = 2, 1 in bilateral lobes, 1 in the right lobe, 18.2%), and lobectomy (n = 1, left lower lobectomy, 9.1%). All patients safely underwent a complete resection. As for postsurgical complications, chylothorax occurred in 1 case and prolonged pulmonary air leakage in 1 case. The histological effects of chemo-targeted therapy were slight. There was no relationship between histological findings with imaging findings obtained prior to the operation (p = 0.63). The 5-year disease-free survival rate after metastasectomy was 10.9%. Conclusions: Pulmonary metastasectomy after chemo-targeted therapy for colorectal carcinoma patients obtained acceptable results. In addition, there was no correlation between imaging and histopathologic results following chemo-targeted therapy

Additional file 3: of Pleuropneumonectomy for a large thymoma with multiple pleural dissemination using median sternotomy followed by posterolateral thoracotomy

Video 3. After reconstruction of the left brachiocephalic vein (BCV) with a polytetrafluoroethylene (PTFE) graft and resection of the right BCV, the right main pulmonary artery and bronchus were resected by a stapler, followed by reconstruction of the right BCV with a PTFE graft. Then, a right posterolateral thoracotomy at the fifth intercostal incision was performed for a pleuropneumonectomy

α1-Antitrypsin attenuates acute rejection of orthotopic murine lung allografts

Background!#!α1-Antitrypsin (AAT) is an acute phase glycoprotein, a multifunctional protein with proteinase inhibitory, anti-inflammatory and cytoprotective properties. Both preclinical and clinical experiences show that the therapy with plasma purified AAT is beneficial for a broad spectrum of inflammatory conditions. The potential effects of AAT therapy have recently been highlighted in lung transplantation (LuTx) as well.!##!Methods!#!We used a murine fully mismatched orthotopic single LuTx model (BALB/CJ as donors and C57BL/6 as recipients). Human AAT preparations (5 mg, n = 10) or vehicle (n = 5) were injected to the recipients subcutaneously prior to and intraperitoneally immediately after the LuTx. No immune suppressive drugs were administered. Three days after the transplantation, the mice were sacrificed, and biological samples were assessed.!##!Results!#!Histological analysis revealed significantly more severe acute rejection in the transplanted lungs of controls than in AAT treated mice (p < 0.05). The proportion of neutrophil granulocytes, B cells and the total T helper cell populations did not differ between two groups. There was no significant difference in serum CXCL1 (KC) levels. However, when compared to controls, human AAT was detectable in the serum of mice treated with AAT and these mice had a higher serum anti-elastase activity, and significantly lower proportion of Th1 and Th17 among all Th cells. Cleaved caspase-3-positive cells were scarce but significantly less abundant in allografts from recipients treated with AAT as compared to those treated with vehicle.!##!Conclusion!#!Therapy with AAT suppresses the acute rejection after LuTx in a mouse model. The beneficial effects seem to involve anti-protease and immunomodulatory activities of AAT